Alnylam Pharmaceuticals, Inc. ALNY

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

• GlobeNewswire Inc. 5 oct

  Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight

  The type 2 diabetes market is projected to experience steady growth through 2036, driven by rising global prevalence, obesity, and adoption of next-generation therapies including GLP-1 receptor agonists and SGLT2 inhibitors. Key emerging drugs from major pharmaceutical companies like Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are expected to reshape the market landscape with improved glycemic control and weight management benefits.

  

• GlobeNewswire Inc. 5 oct

  Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

  Alnylam Pharmaceuticals faces a securities fraud investigation following a significant stock price decline. On July 30, 2026, the company lowered its TTR product sales guidance by approximately $200 million due to slower-than-expected market adoption in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a 28.31% stock price drop, prompting a class action investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders.

  

• GlobeNewswire Inc. 2 oct

  Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

  The Law Offices of Frank R. Cruz is investigating Alnylam Pharmaceuticals for potential federal securities law violations. On July 30, 2026, Alnylam lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to slower-than-expected growth in the ATTR-CM market after initial pent-up demand was satisfied. The announcement triggered a sharp 28.31% stock price decline, causing investor losses.

  

• The Motley Fool 28 sept

  18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.

  Despite being down 35% year-to-date, Alnylam Pharmaceuticals has rebounded 25% since late July and maintains strong analyst support with 18 of 21 analysts rating it as a buy or strong buy. The stock's attractive valuation (19.7x forward earnings, 0.32 PEG ratio) and favorable market dynamics—including reduced competition from a failed rival drug and extended patent protection for Pfizer's competing therapy—support the bullish outlook. However, investors should monitor demand normalization for Amvuttra and potential developments from the failed Wainua trial.

  

• GlobeNewswire Inc. 17 sept

  Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board

  Aerska, a biotechnology company developing RNA medicines for CNS diseases through its antibody-oligonucleotide conjugate (AOC) platform, has appointed Laura Sepp-Lorenzino to its Scientific Advisory Board. Sepp-Lorenzino brings over 30 years of experience in genetic medicines and nucleic acid therapies, previously serving as Chief Scientific Officer at Intellia Therapeutics and leading nucleic acid programs at Vertex Pharmaceuticals.